Biosimilar Sponsors Looking To Avoid ‘Patent Dance’ Turn To Inter Partes Review
Executive Summary
For now, PTO’s post-grant review process lets biosimilar sponsors challenge validity of reference product patents before BPCIA information-exchange provisions kick in; however, a legislative change may be on the horizon.